Stay updated with breaking news from Nasdaq edit. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
JPMorgan Chase & Co. upgraded shares of Editas Medicine (NASDAQ:EDIT – Free Report) from an underweight rating to a neutral rating in a report released on Wednesday morning, Marketbeat Ratings reports. JPMorgan Chase & Co. currently has $8.00 target price on the stock. A number of other brokerages have also recently commented on EDIT. StockNews.com […] ....
Editas Medicine (NASDAQ:EDIT – Get Free Report) was upgraded by investment analysts at JPMorgan Chase & Co. from an “underweight” rating to a “neutral” rating in a research note issued on Wednesday, MarketBeat Ratings reports. The brokerage currently has a $8.00 price objective on the stock. JPMorgan Chase & Co.‘s price objective suggests a potential […] ....
Editas Medicine, Inc. (NASDAQ:EDIT – Get Free Report) has received a consensus recommendation of “Hold” from the fourteen ratings firms that are covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, six have issued a hold recommendation and seven have assigned a buy recommendation to the company. […] ....
Editas Medicine, Inc. (NASDAQ:EDIT – Get Free Report) has been assigned a consensus rating of “Hold” from the fourteen research firms that are currently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, six have assigned a hold recommendation and seven have assigned a buy recommendation to the […] ....
Cambridge Investment Research Advisors Inc. raised its holdings in shares of Editas Medicine, Inc. (NASDAQ:EDIT – Free Report) by 12.7% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 72,992 shares of the company’s stock after purchasing an additional 8,243 shares during the […] ....